Signaling in fibrosis: TGF-β, WNT, and YAP/TAZ converge

Frontiers in Medicine

Volumn 2, Issue SEP, 2015, Pages

  Piersma, Bram ^a   Bank, Ruud A ^a   Boersema, Miriam ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Fibrosis; Hippo; Myofibroblast; Signaling; TGF ; WNT; YAP TAZ

Indexed keywords

EID: 85050910102     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2015.00059     Document Type: Review

References (150)

1. Rockey DC, Bell P, Hill JA. Fibrosis-a common pathway to organ injury and failure. N Engl J Med (2015) 372:1138-49. doi:10.1056/NEJMra1300575
2. Moore-Morris T, Guimarães-Camboa N, Banerjee I, Zambon AC, Kisseleva T, Velayoudon A, et al. Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. J Clin Invest (2014) 124:2921-34. doi:10.1172/JCI74783
3. Humphreys BD, Lin S, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol (2010) 176:85-97. doi:10.2353/ajpath.2010.090517
4. Kramann R, Schneider RK, DiRocco DP, Machado F, Fleig S, Bondzie PA, et al. Perivascular Gli1(+) progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell (2014) 16:51-66. doi:10.1016/j.stem.2014.11.004
5. Hung C, Linn G, Chow YH, Kobayashi A, Mittelsteadt K, Altemeier WA, et al. Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med (2013) 188:820-30. doi:10.1164/rccm.201212-2297OC
6. Hashimoto N, Jin H, Liu T, Chensue SW, Phan SH. Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest (2004) 113:243-52. doi:10.1172/JCI18847
7. Kisseleva T, Uchinami H, Feirt N, Quintana-Bustamante O, Segovia JC, Schwabe RF, et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol (2006) 45:429-38. doi:10.1016/j.jhep.2006.04.014
8. Wada T, Sakai N, Matsushima K, Kaneko S. Fibrocytes: a new insight into kidney fibrosis. Kidney Int (2007) 72:269-73. doi:10.1038/sj.ki.5002325
9. Quaggin SE, Kapus A. Scar wars: mapping the fate of epithelial-mesenchymal-myofibroblast transition. Kidney Int (2011) 80:41-50. doi:10.1038/ki.2011.77
10. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol (2008) 19:2282-7. doi:10.1681/asn.2008050513
11. Xavier S, Vasko R, Matsumoto K, Zullo JA, Chen R, Maizel J, et al. Curtailing endothelial TGF-beta signaling is sufficient to reduce endothelial-mesenchymal transition and fibrosis in CKD. J Am Soc Nephrol (2015) 26:817-29. doi:10.1681/ASN.2013101137
12. Desmoulière A, Tuchweber B, Gabbiani G. Role of the myofibroblast differentiation during liver fibrosis. J Hepatol (1995) 22:61-4
13. Hinz B. Masters and servants of the force: the role of matrix adhesions in myofibroblast force perception and transmission. Eur J Cell Biol (2006) 85:175-81. doi:10.1016/j.ejcb.2005.09.004
14. Gabbiani G, Ryan GB, Majno G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia (1971) 27:549-50. doi:10.1007/BF02147594
15. Hinz B, Celetta G, Tomasek JJ, Gabbiani G, Chaponnier C. Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol Biol Cell (2001) 12:2730-41. doi:10.1091/mbc.12.9.2730
16. Strauch AR, Hariharan S. Dynamic interplay of smooth muscle a-actin gene-regulatory proteins reflects the biological complexity of myofibroblast differentiation. Biology (Basel) (2013) 2:555-86. doi:10.3390/biology2020555
17. van der Slot AJ, Zuurmond AM, van den Bogaerdt AJ, Ulrich MM, Middelkoop E, Boers W, et al. Increased formation of pyridinoline cross-links due to higher telopeptide lysyl hydroxylase levels is a general fibrotic phenomenon. Matrix Biol (2004) 23:251-7. doi:10.1016/j.matbio.2004.06.001
18. Ho YY, Lagares D, Tager AM, Kapoor M. Fibrosis-a lethal component of systemic sclerosis. Nat Rev Rheumatol (2014) 10:390-402. doi:10.1038/nrrheum.2014.53
19. Friedman SL, Sheppard D, Duffield JS, Violette S. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med (2013) 5:167sr1. doi:10.1126/scitranslmed.3004700
20. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol (2002) 3:349-63. doi:10.1038/nrm809
21. Kohan M, Muro AF, White ES, Berkman N. EDA-containing cellular fibronectin induces fibroblast differentiation through binding to alpha4beta7 integrin receptor and MAPK/Erk 1/2-dependent signaling. FASEB J (2010) 24:4503-12. doi:10.1096/fj.10-154435
22. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J (2004) 18:816-27. doi:10.1096/fj.03-1273rev
23. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell (2012) 149:1192-205. doi:10.1016/j.cell.2012.05.012
24. Zilberberg L, Todorovic V, Dabovic B, Horiguchi M, Couroussé T, Sakai LY, et al. Specificity of latent TGF-β binding protein (LTBP) incorporation into matrix: role of fibrillins and fibronectin. J Cell Physiol (2012) 227:3828-36. doi:10.1002/jcp.24094
25. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev (2000) 14:163-76. doi:10.1101/gad.14.2.163
26. Wipff PJ, Hinz B. Integrins and the activation of latent transforming growth factor beta1-an intimate relationship. Eur J Cell Biol (2008) 87:601-15. doi:10.1016/j.ejcb.2008.01.012
27. Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T, et al. Latent TGF-β structure and activation. Nature (2011) 474:343-9. doi:10.1038/nature10152
28. Worthington JJ, Klementowicz JE, Travis MATGF. β: a sleeping giant awoken by integrins. Trends Biochem Sci (2010) 36:47-54. doi:10.1016/j.tibs.2010.08.002
29. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. Mechanism of activation of the TGF-beta receptor. Nature (1994) 370:341-7. doi:10.1038/370341a0
30. Massagué J. TGF-beta signal transduction. Annu Rev Biochem (1998) 67:753-91. doi:10.1146/annurev.biochem.67.1.753
31. Alarcon C, Zaromytidou AI, Xi Q, Gao S, Yu J, Fujisawa S, et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell (2009) 139:757-69. doi:10.1016/j.cell.2009.09.035
32. Aragón E, Goerner N, Zaromytidou AI, Xi Q, Escobedo A, Massagué J, et al. A Smad action turnover switch operated by WW domain readers of a phosphoserine code. Genes Dev (2011) 25:1275-88. doi:10.1101/gad.2060811
33. Massagué J. TGFβ signalling in context. Nat Rev Mol Cell Biol (2012) 13:616-30. doi:10.1038/nrm3434
34. Shi Y, Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell (2003) 113:685-700. doi:10.1016/S0092-8674(03)00432-X
35. Bujak M, Ren G, Kweon HJ, Dobaczewski M, Reddy A, Taffet G, et al. Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation (2007) 116:2127-38. doi:10.1161/CIRCULATIONAHA.107.704197
36. Wang B, Omar A, Angelovska T, Drobic V, Rattan SG, Jones SC, et al. Regulation of collagen synthesis by inhibitory Smad7 in cardiac myofibroblasts. Am J Physiol Heart Circ Physiol (2007) 293:H1282-90. doi:10.1152/ajpheart.00910.2006
37. Dobaczewski M, Bujak M, Li N, Gonzalez-Quesada C, Mendoza LH, Wang XF, et al. Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ Res (2010) 107:418-28. doi:10.1161/CIRCRESAHA.109.216101
38. Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K, Satoh M, et al. Increased expression of transforming growth factor-β1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med (2001) 163:1476-83. doi:10.1164/ajrccm.163.6.9908135
39. Springer J, Scholz FR, Peiser C, Groneberg DA, Fischer A. SMAD-signaling in chronic obstructive pulmonary disease: transcriptional down-regulation of inhibitory SMAD 6 and 7 by cigarette smoke. Biol Chem (2004) 385:649-53. doi:10.1515/BC.2004.080
40. Pulichino A, Wang I, Caron A, Mortimer J, Auger A, Boie Y, et al. Identification of transforming growth factor β1-driven genetic programs of acute lung fibrosis. Am J Respir Cell Mol Biol (2008) 39:324-36. doi:10.1165/rcmb.2007-0186OC
41. Sandbo N, Lau A, Kach J, Ngam C, Yau D, Dulin NO. Delayed stress fiber formation mediates pulmonary myofibroblast differentiation in response to TGF-β. Am J Physiol Lung Cell Mol Physiol (2011) 301:656-66. doi:10.1152/ajplung.00166.2011
42. Liu C, Gaça MD, Swenson E, Vellucci VF, Reiss M, Wells RG. Smads 2 and 3 are differentially activated by transforming growth factor-beta (TGF-beta) in quiescent and activated hepatic stellate cells. Constitutive nuclear localization of Smads in activated cells is TGF-beta-independent. J Biol Chem (2003) 278:11721-8. doi:10.1074/jbc.M207728200
43. Uemura M, Swenson ES, Gaça MD, Giordano FJ, Reiss M, Wells RG. Smad2 and Smad3 play different roles in rat hepatic stellate cell function and a-smooth muscle actin organization. Mol Biol Cell (2005) 16:4214-24. doi:10.1091/mbc.E05-02-0149
44. Kaimori A, Potter J, Kaimori JY, Wang C, Mezey E, Koteish A. Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem (2007) 282:22089-101. doi:10.1074/jbc.M700998200
45. Fukasawa H, Yamamoto T, Togawa A, Ohashi N, Fujigaki Y, Oda T, et al. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci U S A (2004) 101:8687-92. doi:10.1073/pnas.0400035101
46. Fukasawa H, Yamamoto T, Suzuki H, Togawa A, Ohashi N, Fujigaki Y, et al. Treatment with anti-TGF-beta antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-beta signaling. Kidney Int (2004) 65:63-74. doi:10.1111/j.1523-1755.2004.00393.x
47. Poncelet AC, Schnaper H, Tan R, Liu Y, Runyan CE. Cell phenotype-specific down-regulation of Smad3 involves decreased gene activation as well as protein degradation. J Biol Chem (2007) 282:15534-40. doi:10.1074/jbc.M701991200
48. Ishida W, Mori Y, Lakos G, Sun L, Shan F, Bowes S, et al. Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. J Invest Dermatol (2006) 126:1733-44. doi:10.1038/sj.jid.5700303
49. Meng X, Huang X, Chung AC, Qin W, Shao X, Igarashi P, et al. Smad2 protects against TGF-β/Smad3-mediated renal fibrosis. J Am Soc Nephrol (2010) 21:1477-87. doi:10.1681/ASN.2009121244
50. Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JJ, Mizel DE, et al. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol (1999) 1:260-6. doi:10.1038/12971
51. Arany PR, Flanders KC, Kobayashi T, Kuo CK, Stuelten C, Desai KV, et al. Smad3 deficiency alters key structural elements of the extracellular matrix and mechanotransduction of wound closure. Proc Natl Acad Sci U S A (2006) 103:9250-5. doi:10.1073/pnas.0602473103
52. Masszi A, Speight P, Charbonney E, Lodyga M, Nakano H, Szászi K, et al. Fate-determining mechanisms in epithelial-myofibroblast transition: major inhibitory role for Smad3. J Cell Biol (2010) 188:383-99. doi:10.1083/jcb.200906155
53. Burch ML, Zheng W, Little PJ. Smad linker region phosphorylation in the regulation of extracellular matrix synthesis. Cell Mol Life Sci (2011) 68:97-107. doi:10.1007/s00018-010-0514-4
54. Duan WJ, Yu X, Huang XR, Yu JW, Lan HY. Opposing roles for Smad2 and Smad3 in peritoneal fibrosis in vivo and in vitro. Am J Pathol (2014) 184:2275-84. doi:10.1016/j.ajpath.2014.04.014
55. Neelisetty S, Alford C, Reynolds K, Woodbury L, Nlandu-Khodo S, Yang H, et al. Renal fibrosis is not reduced by blocking transforming growth factor-β signaling in matrix-producing interstitial cells. Kidney Int (2015). doi:10.1038/ki.2015.51
56. Mullen AC, Orlando DA, Newman JJ, Lovén J, Kumar RM, Bilodeau S, et al. Master transcription factors determine cell-type-specific responses to TGF-β signaling. Cell (2011) 147:565-76. doi:10.1016/j.cell.2011.08.050
57. Niehrs C. The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol (2012) 13:767-79. doi:10.1038/nrm3470
58. Petersen CP, Reddien PW. Wnt signaling and the polarity of the primary body axis. Cell (2009) 139:1056-68. doi:10.1016/j.cell.2009.11.035
59. van Amerongen R, Mikels A, Nusse R. Alternative wnt signaling is initiated by distinct receptors. Sci Signal (2008) 1:re9. doi:10.1126/scisignal.135re9
60. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J (1997) 16:3797-804. doi:10.1093/emboj/16.13.3797
61. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell (2002) 108:837-47. doi:10.1016/S0092-8674(02)00685-2
62. Davidson G, Wu W, Shen J, Bilic J, Fenger U, Stannek P, et al. Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction. Nature (2005) 438:867-72. doi:10.1038/nature04170
63. Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R, et al. A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature (2005) 438:873-7. doi:10.1038/nature04185
64. Li VS, Ng SS, Boersema PJ, Low TY, Karthaus WR, Gerlach JP, et al. Wnt signaling through inhibition of β-catenin degradation in an intact Axin1 complex. Cell (2012) 149:1245-56. doi:10.1016/j.cell.2012.05.002
65. Bilic J, Huang YL, Davidson G, Zimmermann T, Cruciat CM, Bienz M, et al. Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science (2007) 316:1619-22. doi:10.1126/science.1137065
66. Taelman VF, Dobrowolski R, Plouhinec JL, Fuentealba LC, Vorwald PP, Gumper I, et al. Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes. Cell (2010) 143:1136-48. doi:10.1016/j.cell.2010.11.034
67. Behrens J, von Kries J, Kühl M, Bruhn L, Wedlich D, Grosschedl R, et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature (1996) 382:638-42. doi:10.1038/382638a0
68. Molenaar M, van de Wetering M, Oosterwegel M, Peterson-Maduro J, Godsave S, Korinek V, et al. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell (1996) 86:391-9. doi:10.1016/S0092-8674(00)80112-9
69. Surendran K, McCaul SP, Simon TC. A role for Wnt-4 in renal fibrosis. Am J Physiol Renal Physiol (2002) 282:F431-41. doi:10.1152/ajprenal.0009.2001
70. Kobayashi K, Luo M, Zhang Y, Wilkes DC, Ge G, Grieskamp T, et al. Secreted frizzled-related protein 2 is a procollagen C proteinase enhancer with a role in fibrosis associated with myocardial infarction. Nat Cell Biol (2008) 11:46-55. doi:10.1038/ncb1811
71. Duan J, Gherghe C, Liu D, Hamlett E, Srikantha L, Rodgers L, et al. Wnt1/β-catenin injury response activates the epicardium and cardiac fibroblasts to promote cardiac repair. EMBO J (2012) 31:429-42. doi:10.1038/emboj.2011.418
72. Ye B, Ge Y, Perens G, Hong L, Xu H, Fishbein MC, et al. Canonical Wnt/β-catenin signaling in epicardial fibrosis of failed pediatric heart allografts with diastolic dysfunction. Cardiovasc Pathol (2013) 22:54-7. doi:10.1016/j.carpath.2012.03.004
73. Henderson WR, Chi EY, Ye X, Nguyen C, Tien YT, Zhou B, et al. Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci U S A (2010) 107:14309-14. doi:10.1073/pnas.1001520107
74. Lam AP, Flozak AS, Russell S, Wei J, Jain M, Mutlu GM, et al. Nuclear β-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. Am J Respir Cell Mol Biol (2011) 45:915-22. doi:10.1165/rcmb.2010-0113OC
75. Ulsamer A, Wei Y, Kim KK, Tan K, Wheeler S, Xi Y, et al. Axin pathway activity regulates in vivo pY654-β-catenin accumulation and pulmonary fibrosis. J Biol Chem (2012) 297:5164-72. doi:10.1074/jbc.M111.322123
76. Surendran K, Schiavi S, Hruska KA. Wnt-dependent β-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J Am Soc Nephrol (2005) 16:2373-84. doi:10.1681/ASN.2004110949
77. He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol (2009) 20:765-76. doi:10.1681/ASN.2008060566
78. Hao S, He W, Li Y, Ding H, Hou Y, Nie J, et al. Targeted inhibition of β-catenin/CBP signaling ameliorates renal interstitial fibrosis. J Am Soc Nephrol (2011) 22:1642-53. doi:10.1681/ASN.2010101079
79. Ren S, Johnson BG, Kida Y, Ip C, Davidson KC, Lin SL, et al. LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1. Proc Natl Acad Sci U S A (2013) 110:1440-5. doi:10.1073/pnas.1211179110
80. DiRocco DP, Kobayashi A, Taketo MM, McMahon AP, Humphreys BD. Wnt4/β-catenin signaling in medullary kidney myofibroblasts. J Am Soc Nephrol (2013) 24:1399-412. doi:10.1681/ASN.2012050512
81. Sato M. Upregulation of the Wnt/β-catenin pathway induced by transforming growth factor-β in hypertrophic scars and keloids. Acta Derm Venereol (2006) 86:300-7. doi:10.2340/00015555-0101
82. Wei J, Fang F, Lam AP, Sargent JL, Hamburg E, Hinchcliff ME, et al. Wnt/β-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum (2012) 64:2734-45. doi:10.1002/art.34424
83. Kapoor M, Liu S, Shi-wen X, Huh K, McCann M, Denton CP, et al. GSK-3beta in mouse fibroblasts controls wound healing and fibrosis through an endothelin-1-dependent mechanism. J Clin Invest (2008) 118:3279-90. doi:10.1172/JCI35381
84. Bergmann C, Akhmetshina A, Dees C, Palumbo K, Zerr P, Beyer C, et al. Inhibition of glycogen synthase kinase 3β induces dermal fibrosis by activation of the canonical Wnt pathway. Ann Rheum Dis (2011) 70:2191-8. doi:10.1136/ard.2010.147140
85. Hamburg EJ, Atit RP. Sustained β-catenin activity in dermal fibroblasts is sufficient for skin fibrosis. J Invest Dermatol (2012) 235:686-97. doi:10.1038/jid.2012.155
86. Beyer C, Schramm A, Akhmetshina A, Dees C, Kireva T, Gelse K, et al. β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann Rheum Dis (2012) 71:761-7. doi:10.1136/annrheumdis-2011-200568
87. Distler A, Ziemer C, Beyer C, Lin NY, Chen CW, Palumbo-Zerr K, et al. Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling. Ann Rheum Dis (2014) 73:624-7. doi:10.1136/annrheumdis-2013-203995
88. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci (2003) 116:2627-34. doi:10.1242/jcs.00623
89. Dees C, Schlottmann I, Funke R, Distler A, Palumbo-Zerr K, Zerr P, et al. The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Ann Rheum Dis (2014) 73:1232-9. doi:10.1136/annrheumdis-2012-203194
90. Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell (2005) 122:421-34. doi:10.1016/j.cell.2005.06.007
91. Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol (2007) 17:2054-60. doi:10.1016/j.cub.2007.10.039
92. Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev (2014) 94:1287-312. doi:10.1152/physrev.00005.2014
93. Sudol M, Bork P, Einbond A, Kastury K, Druck T, Negrini M, et al. Characterization of the mammalian YAP (Yes-associated Protein) gene and its role in defining a novel protein module, the WW domain. J Biol Chem (1995) 270:14733-41. doi:10.1074/jbc.270.24.14733
94. Kanai F, Marignani P, Sarbassova D, Yagi R, Hall R, Donowitz M, et al. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J (2000) 19:6778-91. doi:10.1093/emboj/19.24.6778
95. Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science (2005) 309:1074-8. doi:10.1126/science.1110955
96. Wu S, Huang J, Dong J, Pan D. Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell (2003) 114:445-56. doi:10.1016/S0092-8674(03)00549-X
97. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev (2007) 21:2747-61. doi:10.1101/gad.1602907
98. Liu CY, Zha ZY, Zhou X, Zhang H, Huang W, Zhao D, et al. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCFbeta-TrCP E3 ligase. J Biol Chem (2010) 285:37159-69. doi:10.1074/jbc.M110.152942
99. Oka T, Mazack V, Sudol M. Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). J Biol Chem (2008) 283:27534-46. doi:10.1074/jbc.M804380200
100. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev (2010) 24:72-85. doi:10.1101/gad.1843810
101. Vassilev A, Kaneko K, Shu H, Zhao Y, DePamphilis MTEAD./TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev (2001) 15:1229-41. doi:10.1101/gad.888601
102. Zhao B, Ye X, Yu J, Li L, Li W, Li S, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev (2008) 22:1962-71. doi:10.1101/gad.1664408
103. Mahoney WM, Hong JH, Yaffe MB, Farrance IK. The transcriptional co-activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members. Biochem J (2005) 388:217-25. doi:10.1042/BJ20041434
104. Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, et al. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem (2009) 284:13355-62. doi:10.1074/jbc.M900843200
105. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, et al. Role of YAP/TAZ in mechanotransduction. Nature (2011) 474:179-83. doi:10.1038/nature10137
106. Wada K, Itoga K, Okano T, Yonemura S, Sasaki H. Hippo pathway regulation by cell morphology and stress fibers. Development (2011) 138:3907-14. doi:10.1242/dev.070987
107. Sansores-Garcia L, Bossuyt W, Wada K, Yonemura S, Tao C, Sasaki H, et al. Modulating F-actin organization induces organ growth by affecting the Hippo pathway. EMBO J (2011) 30:2325-35. doi:10.1038/emboj.2011.157
108. Liu F, Lagares D, Choi KM, Stopfer L, Marinkovic A, Vrbanac V, et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am J Physiol Lung Cell Mol Physiol (2015) 308:L344-57. doi:10.1152/ajplung.00300.2014
109. Mannaerts I, Leite SB, Verhulst S, Claerhout S, Eysackers N, Thoen LF, et al. The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. J Hepatol (2015) 63:679-88. doi:10.1016/j.jhep.2015.04.011
110. Mitani A, Nagase T, Fukuchi K, Aburatani H, Makita R, Kurihara H. Transcriptional coactivator with PDZ-binding motif is essential for normal alveolarization in mice. Am J Respir Crit Care Med (2009) 180:326-38. doi:10.1164/rccm.200812-1827OC
111. Xin M, Kim Y, Sutherland LB, Murakami M, Qi X, McAnally J, et al. Hippo pathway effector Yap promotes cardiac regeneration. Proc Natl Acad Sci U S A (2013) 110:13839-44. doi:10.1073/pnas.1313192110
112. Lin Z, von Gise A, Zhou P, Gu F, Ma Q, Jiang J, et al. Cardiac-specific YAP activation improves cardiac function and survival in an experimental murine MI model. Circ Res (2014) 115:354-63. doi:10.1161/CIRCRESAHA.115.303632
113. Lee MJ, Ran Byun M, Furutani-Seiki M, Hong JH, Jung HS. YAP and TAZ regulate skin wound healing. J Invest Dermatol (2014) 134:518-25. doi:10.1038/jid.2013.339
114. Carthy JM, Garmaroudi FS, Luo Z, McManus BM. Wnt3a induces myofibroblast differentiation by upregulating TGF-β signaling through SMAD2 in a β-catenin-dependent manner. PLoS One (2011) 6:e19809. doi:10.1371/journal.pone.0019809
115. Lam AP, Herazo-Maya JD, Sennello JA, Flozak AS, Russell S, Mutlu GM, et al. Wnt coreceptor Lrp5 is a driver of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2014) 190:185-95. doi:10.1164/rccm.201401-0079OC
116. Akhmetshina A, Palumbo K, Dees C, Bergmann C, Venalis P, Zerr P, et al. Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun (2012) 3:735. doi:10.1038/ncomms1734
117. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu Y, Grinnell B, et al. The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell (1997) 89:1165-73. doi:10.1016/S0092-8674(00)80303-7
118. Ferrigno O, Lallemand F, Verrecchia F, L'Hoste S, Camonis J, Atfi A, et al. Yes-associated protein (YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGF-beta/Smad signaling. Oncogene (2002) 21:4879-84. doi:10.1038/sj.onc.1205623
119. Han G, Li AG, Liang YY, Owens P, He W, Lu S, et al. Smad7-induced beta-catenin degradation alters epidermal appendage development. Dev Cell (2006) 11:301-12. doi:10.1016/j.devcel.2006.06.014
120. Tang Y, Liu Z, Zhao L, Clemens TL, Cao X. Smad7 stabilizes beta-catenin binding to E-cadherin complex and promotes cell-cell adhesion. J Biol Chem (2008) 283:23956-63. doi:10.1074/jbc.M800351200
121. Liu W, Rui H, Wang J, Lin S, He Y, Chen M, et al. Axin is a scaffold protein in TGF-beta signaling that promotes degradation of Smad7 by Arkadia. EMBO J (2006) 25:1646-58. doi:10.1038/sj.emboj.7601057
122. Furuhashi M, Yagi K, Yamamoto H, Furukawa Y, Shimada S, Nakamura Y, et al. Axin facilitates Smad3 activation in the transforming growth factor beta signaling pathway. Mol Cell Biol (2001) 21:5132-41. doi:10.1128/MCB.21.15.5132-5141.2001
123. Azzolin L, Zanconato F, Bresolin S, Forcato M, Basso G, Bicciato S, et al. Role of TAZ as mediator of Wnt signaling. Cell (2012) 151:1443-56. doi:10.1016/j.cell.2012.11.027
124. Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, et al. YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. Cell (2014) 158:157-70. doi:10.1016/j.cell.2014.06.013
125. Llado V, Nakanishi Y, Duran A, Reina-Campos M, Shelton PM, Linares JF, et al. Repression of intestinal stem cell function and tumorigenesis through direct phosphorylation of beta-catenin and Yap by PKCzeta. Cell Rep (2015) 10:740-54. doi:10.1016/j.celrep.2015.01.007
126. Varelas X, Samavarchi-Tehrani P, Narimatsu M, Weiss A, Cockburn K, Larsen BG, et al. The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-β-SMAD pathway. Dev Cell (2010) 19:831-44. doi:10.1016/j.devcel.2010.11.012
127. Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol (2006) 4:e115. doi:10.1371/journal.pbio.0040115
128. Imajo M, Miyatake K, Iimura A, Miyamoto A, Nishida E. A molecular mechanism that links Hippo signalling to the inhibition of Wnt/β-catenin signalling. EMBO J (2012) 31:1109-22. doi:10.1038/emboj.2011.487
129. Hill CS. Nucleocytoplasmic shuttling of Smad proteins. Cell Res (2009) 19:36-46. doi:10.1038/cr.2008.325
130. Goentoro L, Kirschner MW. Evidence that fold-change, and not absolute level, of beta-catenin dictates Wnt signaling. Mol Cell (2009) 36:872-84. doi:10.1016/j.molcel.2009.11.017
131. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer (2013) 13:97-110. doi:10.1038/nrc3447
132. Chapman HA. Epithelial-mesenchymal interactions in pulmonary fibrosis. Annu Rev Physiol (2011) 73:413-35. doi:10.1146/annurev-physiol-012110-142225
133. Varelas X, Sakuma R, Samavarchi-Tehrani P, Peerani R, Rao BM, Dembowy J, et al. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol (2008) 10:837-48. doi:10.1038/ncb1748
134. Fujii M, Nakanishi H, Toyoda T, Tanaka I, Kondo Y, Osada H, et al. Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFbeta signaling and defects in the Hippo signaling cascade. Cell Cycle (2012) 11:3373-9. doi:10.4161/cc.21397
135. Hiemer SE, Szymaniak AD, Varelas X. The transcriptional regulators TAZ and YAP direct transforming growth factor β-induced tumorigenic phenotypes in breast cancer cells. J Biol Chem (2014) 289:13461-74. doi:10.1074/jbc.M113.529115
136. Zhou B, Liu Y, Kahn M, Ann DK, Han A, Wang H, et al. Interactions between β-catenin and transforming growth factor-β signaling pathways mediate epithelial-mesenchymal transition and are dependent on the transcriptional co-activator cAMP-response element-binding protein (CREB)-binding protein (CBP). J Biol Chem (2012) 287:7026-38. doi:10.1074/jbc.M111.276311
137. Charbonney E, Speight P, Masszi A, Nakano H, Kapus A. beta-catenin and Smad3 regulate the activity and stability of myocardin-related transcription factor during epithelial-myofibroblast transition. Mol Biol Cell (2011) 22:4472-85. doi:10.1091/mbc.E11-04-0335
138. Labbé E, Lock L, Letamendia A, Gorska AE, Gryfe R, Gallinger S, et al. Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. Cancer Res (2007) 67:75-84. doi:10.1158/0008-5472.CAN-06-2559
139. Heidemann M, Hintermair C, Voss K, Eick D. Dynamic phosphorylation patterns of RNA polymerase II CTD during transcription. Biochim Biophys Acta (2013) 1829:55-62. doi:10.1016/j.bbagrm.2012.08.013
140. Estarás C, Benner C, Jones KA. SMADs and YAP compete to control elongation of beta-catenin:LEF-1-recruited RNAPII during hESC differentiation. Mol Cell (2015) 58:780-93. doi:10.1016/j.molcel.2015.04.001
141. Wrighton KH, Lin X, Feng XH. Phospho-control of TGF-beta superfamily signaling. Cell Res (2009) 19:8-20. doi:10.1038/cr.2008.327
142. Gao S, Alarcon C, Sapkota G, Rahman S, Chen PY, Goerner N, et al. Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling. Mol Cell (2009) 36:457-68. doi:10.1016/j.molcel.2009.09.043
143. Zhang S, Fei T, Zhang L, Zhang R, Chen F, Ning Y, et al. Smad7 antagonizes transforming growth factor beta signaling in the nucleus by interfering with functional Smad-DNA complex formation. Mol Cell Biol (2007) 27:4488-99. doi:10.1128/MCB.01636-06
144. Rice LM, Padilla CM, McLaughlin SR, Mathes A, Ziemek J, Goummih S, et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest (2015) 125:2795-807. doi:10.1172/JCI77958
145. Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov (2012) 11:790-811. doi:10.1038/nrd3810
146. Kahn M. Can we safely target the WNT pathway? Nat Rev Drug Discov (2014) 13:513-32. doi:10.1038/nrd4233
147. Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov (2013) 13:63-79. doi:10.1038/nrd4161
148. Lepourcelet M, Chen YPN, France DS, Wang H, Crews P, Petersen F, et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell (2014) 5:91-102. doi:10.1016/S1535-6108(03)00334-9
149. Ghosh AK, Vaughan DE. Fibrosis: is it a coactivator disease. Front Biosci (Elite Ed) (2012) 4:1556-70. doi:10.2741/E480
150. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev (2012) 26:1300-5. doi:10.1101/gad.192856.112